We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Events

ISTH 2023 Congress

ISTH 2023 Congress
Check the link
Events
ISTH 2023 Congress

Bioxodes presented up-to-date preclinical data in intracerebral hemorrhage during the annual ISTH congress 2023 in Montréal.

Valérie PireauxA, Stéphanie DemoulinA, Estelle HessA, Joël TassignonA, Sandrine DerochetteA, Hans WarrinnierA, Godfroid EdmondA

  • A
    Bioxodes SA, Gosselies, Belgium

Documents

Poster ISTH 2023

Title of the abstract

Evaluation of Hemorrhage and Edema Expansion, Including Effect on Neutrophil-Mediated Neuroinflammation in Intracerebral Hemorrhage, Using Ir-CPI, a Thromboinflammation Inhibitor

Background

Intracerebral hemorrhage (ICH) is a subtype of stroke with a high mortality and functional disability rate. The inflammation and coagulation responses after ICH would accelerate the formation of perihematomal edema (PHE), resulting in brain herniation-related death and neurological deficits. Patients with ICH also frequently present with thrombotic events, including secondary intracerebral ischemic lesions and in-hospital thromboembolic complications. However, medical treatments for inflammation and safe prevention of thrombosis are lacking during the hyperacute phase of ICH. Ixodes ricinus-Contact Phase Inhibitor (Ir-CPI) is an inhibitor of both coagulation factors (Factors XIIa and XIa) and neutrophils, with proven antithrombotic effect in various animal models.

Aims

We evaluated the effects of Ir-CPI on PHE and hemorrhage volumes, on neutrophil infiltration and neuronal degeneration in mice using an ICH model.

Methods

ICH was induced by injecting collagenase into the right striatum. Mice were allocated to either PBS, Ir-CPI (30.7 mg/kg + 8.3 mg/kg/h) or enoxaparin (20 mg/kg) (n = [6-8]). Treatments were administered intravenously immediately after stroke induction as a bolus followed by a 3-day infusion. Dose of Ir-CPI used was previously proven to be antithrombotic in mice. P-values were calculated using a Kruskal-Wallis test with Dunn's multiple comparison test.

Results

Ir-CPI did not increase PHE and hemorrhage volumes measured by magnetic resonance imaging 1 and 3 days after ICH, as compared to PBS. Ir-CPI decreased neutrophil infiltration and significantly decreased the number of neutrophil-releasing NETs at collagenase injection site (p < 0.05). Ir-CPI also reduced the number of degenerating neurons in the hemorrhagic zone (p < 0.05 at the injection site). In contrast, enoxaparin increased PHE and hemorrhage volumes as compared to Ir-CPI (p < 0.05) and PBS and had no significant impact on neutrophil infiltration and degenerating neurons.

Conclusions

Ir-CPI administration after ICH induction is safe, reduces neutrophil infiltration including neutrophil-releasing NETs, and attenuates neuronal degeneration.